Yifan Pharmaceutical announced that on November 4, 2026, Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” of the application for registration and marketing of vinblastine sulfate injection domestically produced drugs issued by the State Drug Administration. This drug is suitable for palliative treatment of malignant tumors such as Hodgkin's lymphoma, and is registered as a chemical class 3. According to IQVIA data, the global sales volume of vinblastine sulfate injections in 2025 is about US$1.31 million. As of the announcement disclosure date, the company invested about 3.466,400 yuan in R&D in this project.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.